Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 31, 2006

View Archived Issues

GRIMs: Novel cytokine-driven tumor suppressors

Anticoagulant proteins potentially useful for pneumonia and ARDS

Antigenics rounds up Q2 developments

Eisai reviews highlights of quarter

Antiallodynic effects of NAALADase inhibition in an in vivo model of neuropathic pain

IL-22: a novel target for autoimmune and inflammatory diseases

HIF-1alpha inhibition enhances antitumor activity of temozolomide

Oncolys BioPharma cleared to begin U.S. clinical trials of telomelysin

U. of Pittsburgh awarded NIAID grant for avian flu vaccine

Antisoma to study AS-1409 in renal cancer and melanoma

Agreement to study AE-37 in prostate cancer in Europe

Pharmexa cleared to begin phase Ib study of HIV vaccine EP-1090

Enrollment open in pivotal study of pralatrexate for peripheral T-cell lymphoma

U.S. DHS certifies BioThrax as approved product for homeland security

Bionomics profiles lead programs

BioDiem signs CRADA with CDC to develop bird flu vaccine

Caprospinol shows favorable results in acute toxicity study

Recent Cardiome patent describes new treatment options for cardiovascular disease

Chrysalin fails to meet primary endpoint in fracture repair

New agents for treating respiratory disorders reported in recent patent literature

Novel treatment options for inflammatory disorders disclosed in recent patents

Recent Synta patent describes novel immunosuppressant agents

German approval for Foster in asthma

Zensana NDA accepted for review

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...